tiprankstipranks
Blurbs

Mizuho Securities Reaffirms Their Hold Rating on Incyte (INCY)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Incyte (INCYResearch Report), with a price target of $95.00. The company’s shares closed yesterday at $66.18.

According to TipRanks, Goldstein is a 2-star analyst with an average return of -0.7% and a 32.51% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Adaptimmune Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $84.77 average price target.

See the top stocks recommended by analysts >>

INCY market cap is currently $14.72B and has a P/E ratio of 15.57.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles